Avita Medical, Inc. RCEL
We take great care to ensure that the data presented and summarized in this overview for AVITA Medical, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RCEL
View all-
Black Rock Inc. New York, NY1.78MShares$22.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.42MShares$17.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA594KShares$7.44 Million0.0% of portfolio
-
State Street Corp Boston, MA520KShares$6.51 Million0.0% of portfolio
-
Essex Investment Management CO LLC Boston, MA231KShares$2.89 Million0.46% of portfolio
-
Northern Trust Corp Chicago, IL216KShares$2.71 Million0.0% of portfolio
-
Awm Investment Company, Inc. New York, NY98.2KShares$1.23 Million0.14% of portfolio
-
Morgan Stanley New York, NY97.4KShares$1.22 Million0.0% of portfolio
-
Jane Street Group, LLC New York, NY89.4KShares$1.12 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY85.3KShares$1.07 Million0.0% of portfolio
Latest Institutional Activity in RCEL
Top Purchases
Top Sells
About RCEL
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
Insider Transactions at RCEL
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 05
2024
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
975
+2.03%
|
$11,700
$12.47 P/Share
|
Nov 29
2024
|
David D O'Toole CFO |
BUY
Grant, award, or other acquisition
|
Direct |
785
+3.33%
|
$5,495
$7.83 P/Share
|
Aug 19
2024
|
Robert Mc Namara |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+21.86%
|
$90,000
$9.0 P/Share
|
Jun 05
2024
|
Lou Panaccio |
BUY
Grant, award, or other acquisition
|
Direct |
9,200
+16.55%
|
-
|
Jun 05
2024
|
Suzanne Crowe |
BUY
Grant, award, or other acquisition
|
Direct |
9,200
+20.16%
|
-
|
Jun 05
2024
|
Jeremy Curnock Cook |
BUY
Grant, award, or other acquisition
|
Direct |
9,200
+23.58%
|
-
|
Jun 05
2024
|
Jan Stern Reed |
BUY
Grant, award, or other acquisition
|
Direct |
9,200
+18.33%
|
-
|
Jun 05
2024
|
Robert Mc Namara |
BUY
Grant, award, or other acquisition
|
Direct |
9,200
+26.32%
|
-
|
Jun 05
2024
|
Cary Guy Vance |
BUY
Grant, award, or other acquisition
|
Direct |
9,200
+26.32%
|
-
|
May 31
2024
|
Donna Shiroma General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
2,225
+4.62%
|
$17,800
$8.17 P/Share
|
May 31
2024
|
David D O'Toole CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,240
+9.25%
|
$17,920
$8.17 P/Share
|
May 30
2024
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
1,000
+2.5%
|
$8,000
$8.9 P/Share
|
Feb 28
2024
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
1,250
+3.22%
|
$21,250
$17.41 P/Share
|
Dec 26
2023
|
James Corbett CEO |
SELL
Open market or private sale
|
Direct |
1,445
-11.09%
|
$18,785
$13.29 P/Share
|
Dec 13
2023
|
Jeremy Curnock Cook |
SELL
Open market or private sale
|
Direct |
2,518
-10.89%
|
$30,216
$12.27 P/Share
|
Dec 12
2023
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
950
+5.15%
|
$11,400
$12.45 P/Share
|
Dec 01
2023
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
500
+2.94%
|
$5,000
$10.68 P/Share
|
Nov 30
2023
|
Donna Shiroma General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
1,469
+3.25%
|
$13,221
$9.06 P/Share
|
Nov 30
2023
|
David D O'Toole CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1,034
+6.06%
|
$9,306
$9.06 P/Share
|
Nov 21
2023
|
David D O'Toole CFO |
BUY
Open market or private purchase
|
Direct |
2,000
+6.46%
|
$20,000
$10.28 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 70.5K shares |
---|---|
Open market or private purchase | 4.18K shares |
Open market or private sale | 3.96K shares |
---|